Latest filing published 18 Apr 2018 for Galectin Therapeutics INC, €2,874.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 6 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +78.0%Entry US$2.36 · Close at T+365 US$4.20
- +45.8%Entry US$1.44 · Close at T+365 US$2.10
- +33.3%Entry US$1.62 · Close at T+365 US$2.16
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Theodore Daniel Zucconi: trading record in brief
Theodore Daniel Zucconi is a declared insider of Galectin Therapeutics Inc, with filings sourced from SEC (Form 4). Over a trading history stretching from 11 December 2007 to 16 April 2018, the count stands at 11 filings.
Both buying and selling appear: 6 purchases worth €3,730, against 1 sale worth €12k. On balance, insiders were net sellers of €7,833. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 1 share grant and 2 option exercises. So far in 2018, the count stands at no purchases and 1 sale.
The median purchase comes to €347. Looking at 6 purchases old enough to measure, the stock rose over the following 90 days in 0% of cases; the median change was -44.4%. Past outcomes like these are no guarantee of what comes next.
On 18 April 2018 came the latest disclosure, an option exercise for €2,874 in Galectin Therapeutics Inc. The last insider purchase was made public on 24 May 2017, 3,456 days ago. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Theodore Daniel Zucconi
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 4,000 shares@ US$0.8917.5% of flowCommon StockSEC:0001179022-18-000026:0
- 4,000 shares@ US$3.5870.2% of flowCommon StockSEC:0001179022-18-000026:1
- 1,000 shares@ US$2.2712.3% of flowCommon stockSEC:0001179022-17-000029:0Canonical exit: 21 Aug 2017 (T+90)
- 370,000 shares@ US$0.23Common StockSEC:0001181431-11-020296:0
- 500,000 shares0Common StockSEC:0001181431-09-009830:0
- 1,700 shares@ US$0.2299Common StockSEC:0001181431-08-054136:0Canonical exit: 18 Dec 2008 (T+90)
- 300 shares@ US$0.20Common StockSEC:0001181431-08-054136:1Canonical exit: 18 Dec 2008 (T+90)
- 3,000 shares@ US$0.1999Common StockSEC:0001181431-08-054069:0Canonical exit: 17 Dec 2008 (T+90)
- 2,000 shares@ US$0.20Common StockSEC:0001181431-08-054069:1Canonical exit: 17 Dec 2008 (T+90)
- 4,000 shares@ US$0.2498Common StockSEC:0001181431-08-054069:2Canonical exit: 17 Dec 2008 (T+90)
- 32 shares0Common StockSEC:0001181431-07-077310:0
11 of 11 declarations
